MEDICINOVA INC
No SEC Form 4 filings for $MNOV in the last 30 days.
See all $MNOV insider activity →Arcturus Therapeutics (ARCT), MediciNova (MNOV), Inovio (INO), and Eyepoint Pharmaceuticals (EYPT) have upcoming binary events. ARCT has Phase II OTC-deficiency data and a Q4 cystic-fibrosis decision. MNOV expects Phase II data in September and COMBAT-ALS readout by year-end. INO awaits an FDA decision on INO-3107 in October. EYPT anticipates LUCIA Phase III data in Q4. All face significant binary risk.
MediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.
MEDICINOVA INC (MNOV) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. Termination of Standby Equity Purchase Agreement On August 31, 2026, MediciNova, Inc. (the “Company”) delivered to YA II PN, LTD. (“Yorkville”), a Notice of Termination, informing Yorkville of the Company’s election to ter
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MNOV (MEDICINOVA INC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent MNOV coverage spans financial news, corporate actions and sector analysis.
Large near‑term catalyst density could drive a sharp move.
Short‑term price spike likely driven by speculative buying on recent trial updates.
Termination removes the option to sell up to $30 M of shares, eliminating potential dilution and future cash inflow.
The new compensation packages increase fixed salary and potential severance payouts, which may affect cost structure and investor perception of management stability.
Enrollment completion in an NIH-funded expanded-access program reduces execution risk and supports a clearer path to subsequent data analysis and scientific presentations.
AlphAI scores every news story that mentions MNOV with an AI model for sentiment and relevance, and aggregates insider trades from MEDICINOVA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Arcturus Therapeutics (ARCT), MediciNova (MNOV), Inovio (INO), and Eyepoint Pharmaceuticals (EYPT) have upcoming binary events. ARCT has Phase II OTC-deficiency data and a Q4 cystic-fibrosis decision. MNOV expects Phase II data in September and COMBAT-ALS readout by year-end. INO awaits an FDA decision on INO-3107 in October. EYPT anticipates LUCIA Phase III data in Q4. All face significant binary risk.
2 min readMediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.
3 min readMEDICINOVA INC (MNOV) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. Termination of Standby Equity Purchase Agreement On August 31, 2026, MediciNova, Inc. (the “Company”) delivered to YA II PN, LTD. (“Yorkville”), a Notice of Termination, informing Yorkville of the Company’s election to ter
1 min readMEDICINOVA INC (MNOV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 17, 2026, MediciNova, Inc. (the “Company”) entered into new Executive Employment Agreements (collectively, the “A
2 min readMediciNova (NASDAQ: MNOV) said it reached enrollment of 200 patients in the NIH-funded SEANOBI-ALS expanded-access study (NCT 06743776) evaluating MN-166 (ibudilast) in ALS. The program is for patients not eligible for randomized trials. Final follow-ups are expected to finish in early 2027 for data analysis and presentations.
3 min readMEDICINOVA INC (MNOV) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001226616 false 0001226616 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23,
2 min readMedicinova reported $0.41 million in revenue for the year ended December 31, 2025, primarily from a Mayo clinical services agreement, and a net loss per common share of $(0.24). The company's net loss was $(12.00) million and operating loss was $(13.28) million, attributed to continued investment in R&D and general corporate expenses. Medicinova is advancing clinical programs for MN-166 and MN-001 and has secured capital access through a structured equity purchase agreement and an at-the-market facility to support operations into 2026.
3 min readMediciNova announced it has enrolled 100 patients in its SEANOBI study for the ALS drug MN-166, reaching 50% of its target. The company's stock has seen significant gains, and the drug holds Orphan Drug and Fast Track designations. MN-166 is also being evaluated in other trials and for various conditions beyond ALS.
2 min readD. Boral Capital has maintained a Buy recommendation for MediciNova (MNOV). The average one-year price target suggests a 357.69% upside, with institutional ownership showing some increases in certain funds, though overall shares owned by institutions decreased. The put/call ratio indicates a bullish outlook for the stock.
2 min readLA JOLLA, Calif., Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market ( NASDAQ:MNOV ) and the Standard Market of the Tokyo Stock Exchange ( Code Number: 4875 ) , is pleased to announce the appointment of Dr. Christopher D.
2 min read
